Table 2: Effectiveness of antianemic treatments in German routine practice.

Operable solid tumor ()Inoperable solid tumor ()Hematological malignancy ()
Day 1 treatmentTransfusionESAIV ironESA + IV ironTransfusionESAIV ironESA + IV ironTransfusionESAIV ironESA + IV iron

Hb(max) [g/dL]
78411811257797127673475
 Median2.92.72.02.62.72.62.02.32.62.62.02.9
 Mean ± StD3.1 ± 1.53.0 ± 1.42.3 ± 1.22.8 ± 1.32.8 ± 1.82.8 ± 1.52.0 ± 1.62.5 ± 1.32.6 ± 1.52.5 ± 1.92.6 ± 1.52.8 ± 1.5
Hb(final) [g/dL]
63401611223776726623275
 Median1.62.01.61.71.51.91.11.81.22.12.02.3
 Mean ± StD2.0 ± 1.82.1 ± 1.21.7 ± 1.52.1 ± 1.31.6 ± 1.52.1 ± 1.71.3 ± 1.51.9 ± 1.51.6 ± 1.81.9 ± 2.02.4 ± 1.62.2 ± 1.9
Responders
63401611223776726623275
 %50.872.562.563.641.355.843.357.735.559.457.180.0
Transfusions
114513012362108102349537107
 Weeks 1–4 [%]100.025.513.38.3100.026.916.717.6100.029.710.0
 Weeks 5–8 [%]24.65.96.731.514.89.82.944.210.810.014.3
 Weeks 9–12 [%]17.53.93.326.28.37.85.933.721.620.0

Number of patients for whom variable is documented or could be calculated.
The maximal difference between the baseline Hb and the highest Hb documented.
The difference between the baseline Hb and the last Hb documented within the 12-week observation period, but at least 4 weeks after the start of treatment.
A responder is defined as a patient with final Hb > 11 g/dL or with Hb(final) of ≥ 1.5 g/dL, with final Hb being the last documented Hb within the observation period, but at least 4 weeks after the start of antianemic treatment.